Stockscreener 앱 받기
0.635
2.25%
-0.0146
시간 외 거래:
.65
0.015
+2.36%
전일 마감가:
$0.6496
열려 있는:
$0.64
하루 거래량:
1.30M
Relative Volume:
1.43
시가총액:
$80.13M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-0.4811
EPS:
-1.32
순현금흐름:
$-117.73M
1주 성능:
-9.29%
1개월 성능:
-18.06%
6개월 성능:
-33.03%
1년 성능:
-16.25%
1일 변동 폭
$0.6251
$0.6589
1주일 범위
$0.6251
$0.7178
52주 변동 폭
$0.6251
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
0.635 | 80.13M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTI stock touches 52-week low at $0.65 amid market challenges By Investing.com - Investing.com South Africa
KPTI stock touches 52-week low at $0.65 amid market challenges - Investing.com Canada
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Karyopharm Therapeutics Inc.'s SWOT analysis: oncology firm's stock faces pivotal trials - Investing.com
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - The Eastern Progress Online
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - Kilgore News Herald
Karyopharm Appoints Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - citybiz
Karyopharm CEO Richard Paulson sells $2,932 in stock By Investing.com - Investing.com Nigeria
Karyopharm CEO Richard Paulson sells $2,932 in stock - Investing.com
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - Defense World
Karyopharm Engages with FDA on Cancer Trial Plans - TipRanks
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Large Growth in Short Interest - MarketBeat
Karyopharm reports inducement grants under Nasdaq listing rule - TipRanks
Karyopharm Therapeutics Awards 4,800 RSUs to New Employees in Retention Plan - StockTitan
Karyopharm Therapeutics (STU:25K) Operating Cash Flow per S - GuruFocus.com
KPTI (Karyopharm Therapeutics) Market Cap : $109.8 Mil (As of Nov. 26, 2024) - GuruFocus.com
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com - Defense World
Karyopharm Therapeutics' SWOT analysis: oncology stock faces pivotal trials - Investing.com
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.
Karyopharm Therapeutics to Present at Piper Sandler Healthcare Conference | KPTI Stock News - StockTitan
Karyopharm appoints new chief accounting officer By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm appoints new chief accounting officer - Investing.com India
Karyopharm Therapeutics Appoints Kristin Abate Chief Accounting Officer - citybiz
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer - Citizentribune
Karyopharm Therapeutics Appoints New Chief Accounting Officer - TipRanks
Karyopharm appoints Kristin Abate as Chief Accounting Officer - TipRanks
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire
Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat
GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Karyopharm Therapeutics Inc 주식 (KPTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Nov 05 '24 |
Sale |
0.91 |
3,675 |
3,346 |
1,131,932 |
| Paulson Richard A. | President and CEO |
Oct 04 '24 |
Sale |
0.88 |
3,607 |
3,172 |
1,135,607 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 04 '24 |
Sale |
0.72 |
3,971 |
2,866 |
273,881 |
| Paulson Richard A. | President and CEO |
Sep 04 '24 |
Sale |
0.72 |
3,667 |
2,647 |
1,139,214 |
| Mason Michael | EVP, CFO & Treasurer |
Sep 04 '24 |
Sale |
0.72 |
7,050 |
5,089 |
391,054 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 04 '24 |
Sale |
0.72 |
5,356 |
3,866 |
404,051 |
| Paulson Richard A. | President and CEO |
Aug 06 '24 |
Sale |
0.93 |
3,608 |
3,355 |
1,142,881 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 30 '24 |
Sale |
1.06 |
2,883 |
3,056 |
326,628 |
| Paulson Richard A. | President and CEO |
Jul 05 '24 |
Sale |
0.85 |
3,616 |
3,077 |
1,146,489 |
| PAKIANATHAN DEEPIKA | Director |
Jun 05 '24 |
Sale |
0.96 |
468,044 |
448,480 |
3,385 |
2.88%
2.65%
자본화:
|
볼륨(24시간):